Why the study?
TD.HK01 is potentially aimed at the preventive treatment of cardiovascular disease and myocardial infarction, prompting evaluation of its potential cardiovascular protective effect in an isoproterenol-induced rat model.
Does TD.HK01® pretreatment prevent or reduce myocardial injury in a rat model of isoproterenol-induced myocardial infarction?
Does TD.HK01® pretreatment prevent or reduce myocardial injury in a rat model of isoproterenol-induced myocardial infarction?
Pretreatment with TD.HK01® demonstrated potential cardiovascular protective effects against isoproterenol-induced myocardial infarction in a rat model.
TD.HK01® consists of a Japanese traditional medicine: Nattokinase (derived from soybean) and three other natural components, namely dried Hirudo medicinalis, Semen Mucuna interrupta and Huperzia carinata. TD.HK01® is potentially aimed to the preventive treatment of cardiovascular disease (CVD) in general, and myocardial infarction (MI) in particular. In this study, a non-invasive method has been used to induce MI in rats, preceded by oral administration of TD.HK01® for 30 consecutive days to determine the potential cardiovascular effect of this pretreatment. Rats were divided into four groups: normal control group, ISO-induced group (isoproterenol (ISO), 150 mg/kg, s.c.) and two groups treated by TD.HK01® in different doses (0.31 and 0.92 g/kg, orally + ISO 150 mg/kg, s.c.). TD.HK01® treated groups showed significant improvement as in abnormal electrocardiography (ECG) alteration ratio, in decreased biochemical specific markers troponin T and in decreased non-specific biochemical markers (LDH and AST) between each of TD.HK01® treated groups and ISO-induced group. The effect on vascular system was also evaluated through serum eNOS quantification and a notable increase in an anti-oxidative enzyme catalase. All three groups, except the normal control one, had pathological lesions in histopathology in different levels - modest injuries in treated groups and more severe in ISO-induced group. It is concluded on the basis of the findings that isoproterenol induced MI in all three groups and TD.HK01® did have its potential protective effect in vivo on cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: